84 related articles for article (PubMed ID: 4242310)
21. Anticancer activity of regional lymph nodes.
Orita K
Panminerva Med; 1975; 17(5-6):170-3. PubMed ID: 1161314
[No Abstract] [Full Text] [Related]
22. Antitumor effect of carboplatin combined with hyperthermia on Ehrlich-ascites tumor in vivo.
Mizuuchi H; Yoshiga K; Sakurai K; Tsumura M; Takada K
Anticancer Res; 1996; 16(1):381-7. PubMed ID: 8615640
[TBL] [Abstract][Full Text] [Related]
23. On the possible use of a new boron compound, hydroxysalicylhydroxamato boron(III), and ultrasound in the treatment of female mice bearing the Ehrlich ascites carcinoma cells.
Ghosh P; Sur P; Bag SP; Sur B; Chatterjee SN
Neoplasma; 1998; 45(6):384-8. PubMed ID: 10210114
[TBL] [Abstract][Full Text] [Related]
24. Resistance and susceptibility to tumours. VI. Reaction of labelled lymphoid cells transferred into the site of previously implanted carcinoma.
Dvorák R; Lindner J
Neoplasma; 1971; 18(1):63-86. PubMed ID: 5575435
[No Abstract] [Full Text] [Related]
25. The influence of three newly synthesized pyrimidine-containing compounds on micronucleus induction and tumor growth.
Nersesyan A; Muradyan R; Arsenyan F
J BUON; 2007; 12(4):521-7. PubMed ID: 18067211
[TBL] [Abstract][Full Text] [Related]
26. Investigations on mononuclear cells of animals sensitized against homologous normal tissue transplants and tumor transplants.
Warnatz H
Arch Immunol Ther Exp (Warsz); 1966; 14(6):748-52. PubMed ID: 5334579
[No Abstract] [Full Text] [Related]
27. Chemotherapeutic potential of two gallic acid derivative compounds from leaves of Casearia sylvestris Sw (Flacourtiaceae).
Da Silva SL; Chaar Jda S; Yano T
Eur J Pharmacol; 2009 Apr; 608(1-3):76-83. PubMed ID: 19222998
[TBL] [Abstract][Full Text] [Related]
28. Possible role of glutathione in the antitumor effect of a copper-containing synthetic superoxide dismutase in mice.
Oberley LW; Rogers KL; Schutt L; Oberley TD; Leuthauser SW; Sorenson JR
J Natl Cancer Inst; 1983 Nov; 71(5):1089-94. PubMed ID: 6580486
[TBL] [Abstract][Full Text] [Related]
29. Differentiation of host-mediated antitumor agents from mitotic posons by the antitumor foot-pad reaction in Ehrlich carcinoma-ddY mouse system.
Abe S; Ohkuma M; Yamazaki M; Mizuno D
Gan; 1976 Oct; 67(5):685-92. PubMed ID: 1017584
[TBL] [Abstract][Full Text] [Related]
30. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
Inoue M; Plautz GE; Shu S
Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
[TBL] [Abstract][Full Text] [Related]
31. [Effects of various antitumor agents on intracerebrally inoculated Ehrlich ascites carcinoma in mice (author's transl)].
Zhou JX; He GH; Tao LX; Xu B
Zhongguo Yao Li Xue Bao; 1981 Dec; 2(4):256-61. PubMed ID: 6462026
[No Abstract] [Full Text] [Related]
32. [Regulation of tumor cell growth by the tumor-bearing host (author's transl)].
Tanino T
Tanpakushitsu Kakusan Koso; 1973 Oct; 18(10):947-59. PubMed ID: 4588293
[No Abstract] [Full Text] [Related]
33. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
[TBL] [Abstract][Full Text] [Related]
34. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor.
Yamamoto N; Naraparaju VR
Cancer Res; 1997 Jun; 57(11):2187-92. PubMed ID: 9187119
[TBL] [Abstract][Full Text] [Related]
36. [Daunomycin and antitumor immunologic defense: its influence on the growth of Ehrlich ascites cancer].
Nicolin A; Beretta G
Arch Ital Patol Clin Tumori; 1969; 12(1):69-78. PubMed ID: 5396285
[No Abstract] [Full Text] [Related]
37. Inhibition of transforming growth factor-beta-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types.
Fujita T; Teramoto K; Ozaki Y; Hanaoka J; Tezuka N; Itoh Y; Asai T; Fujino S; Kontani K; Ogasawara K
Cancer Res; 2009 Jun; 69(12):5142-50. PubMed ID: 19491278
[TBL] [Abstract][Full Text] [Related]
38. An opposing time-dependent immune-modulating effect of the sympathetic nervous system conferred by altering the cytokine profile in the local lymph nodes and spleen of mice with type II collagen-induced arthritis.
Härle P; Möbius D; Carr DJ; Schölmerich J; Straub RH
Arthritis Rheum; 2005 Apr; 52(4):1305-13. PubMed ID: 15818682
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapeutic potential of the volatile oils from Zanthoxylum rhoifolium Lam leaves.
da Silva SL; Figueiredo PM; Yano T
Eur J Pharmacol; 2007 Dec; 576(1-3):180-8. PubMed ID: 17716654
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of sediment fractions from Fusobacterium nucleatum culture supernatant.
Tamai K; Watanabe K; Maeda T
Jpn J Exp Med; 1984 Aug; 54(4):159-70. PubMed ID: 6513099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
